Skip to main content


Peer Reviewed Articles

1. Pal U, Dai J, Li X, Neelakanta G, Luo P, Kumar M, Wang P, Yang X, Anderson JF, Fikrig E. A differential role for BB0365 in the persistence of Borrelia burgdorferi in mice and ticks. Journal of Infectious Diseases. 2008; 197:148-55

2. Li X, Neelakanta G, Liu X, Beck DS, Kantor FS, Fish D, Anderson JF, Fikrig E. The role of outer surface protein D in the Borrelia burgdorferi life cycle. Infection and Immunity 2007; 75:4237-44

3. Neelakanta G, Li X, Pal U, Liu X, Beck DS, DePonte K, Fish D, Kantor FS, Fikrig E. Outer surface protein B is critical for Borrelia burgdorferi adherence and survival within Ixodes ticks. PLoS Pathogens 2007; 3:e33

4. Li X, Pal U, Ramamoorthi N, Liu X, Desrosiers DC, Eggers CH, Anderson JF, Radolf JD, Fikrig E. The Lyme disease agent Borrelia burgdorferi requires BB0690, a Dps homologue, to persist within ticks. Molecular Microbiology 2007; 63:694-710

5. Hovius JW, Li X, Ramamoorthi N, van Dam AP, Barthold SW, van der Poll T, Speelman P, Fikrig E. Coinfection with Borrelia burgdorferi sensu stricto and Borrelia garinii alters the course of murine Lyme borreliosis. FEMS Immunology and Medical Microbiology 2007; 49:224-34

6. Li X, Liu X, Beck DS, Kantor FS, Fikrig E. Borrelia burgdorferi lacking BBK32, a fibronectin-binding protein, retains full pathogenicity. Infection and Immunity 2006; 74:3305-13

7. Xu Q, Seemanapalli SV, Lomax L, McShan K, Li X, Fikrig E, Liang FT. Association of linear plasmid 28-1 with an arthritic phenotype of Borrelia burgdorferi. Infection and Immunity 2005; 73: 7208-7215

8. Pal U, Li X, Wang T, Montgomery RR, Ramamoorthi N, Norgard M, deSilva AM, Bao F, Yang X, Pypaert M, Pradhan D, Kantor FS, Telford S, Anderson JF and Fikrig E. TROSPA, an Ixodes scapularis receptor for Borrelia burgdorferi. Cell 2004; 119: 457-68

9. Li X, Erbe JL, Lockatell CV, Johnson DE, Jobling MG, Holmes RK and Mobley HLT. Use of a translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis. Infection and Immunity 2004; 72: 7306-10

10. Burall LS, Harro JM, Li X, Lockatell CV, Himpsl SD, Hebel JR, Johnson DE, Mobley HLT. Proteus mirabilis genes that contribute to pathogenesis of urinary tract infection: identification of 25 signature-tagged mutants attenuated at least 100-fold. Infection and Immunity 2004; 72: 2922-38

11. Li X, Lockatell CV, Johnson DE, Lane MC, Warren JW, Mobley HLT. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis. Infection and Immunity 2002; 72: 66-75

12. Li X, Lockatell CV, Johnson DE, and Mobley HLT. Identification of MrpI as the sole recombinase that regulates the phase variation of MR/P fimbriae, a bladder colonization factor of uropathogenic Proteus mirabilis. Molecular Microbiology 2002; 45:865-74

13. Li X and Mobley HLT. Vaccines for Proteus mirabilis in urinary tract infection. International Journal of Antimicrobial Agents 2002; 19:461-5

14. Li X, Zhao H, Lockatell CV, Drachenberg CB, Johnson DE, and Mobley HLT. Visualization of Proteus mirabilis within the matrix of urease-induced bladder stones during experimental urinary tract infection. Infection and Immunity 2002; 70:389-94

15. Rasko DA, Phillips JA, Li X, and Mobley HLT. Identification of DNA sequences from a second pathogenicity island of uropathogenic Escherichia coli CFT073: probes specific for uropathogenic populations. Journal of Infectious Diseases 2001; 184:1041-9

16. Li X, Rasko DA, Lockatell CV, Johnson DE, and Mobley HLT. Repression of bacterial motility by a novel fimbrial gene product. EMBO Journal 2001; 20:4854-62

17. Li X, Johnson DE, and Mobley HLT. Requirement of MrpH for mannose-resistant Proteus-like fimbria-mediated hemagglutination by Proteus mirabilis. Infection and Immunity 1999; 67:2822-33

18. Zhao H, Li X, Johnson DE, and Mobley HLT. Identification of protease and rpoN-associated genes of uropathogenic Proteus mirabilis by negative selection in a mouse model of ascending urinary tract infection. Microbiology 1999; 145:185-95

19. Li X and Mobley HLT. MrpB functions as the terminator for assembly of Proteus mirabilis mannose-resistant Proteus-like fimbriae. Infection and Immunity 1998; 66:1759-63

20. Li X, Zhao H, Geymonat L, Bahrani F, Johnson DE, and Mobley HLT. Proteus mirabilis mannose-resistant, Proteus-like fimbriae: MrpG is located at the fimbrial tip and is required for fimbrial assembly. Infection and Immunity 1997; 65:1327-34

21. Zhao H, Li X, Johnson DE, Blomfield I, and Mobley HLT. In vivo phase variation of MR/P fimbrial gene expression in Proteus mirabilis infecting the urinary tract. Molecular Microbiology 1997; 23:1009-19

22. Chang J, Li X, He X, Lu Q, Yu H, Cai W, Li C, and Zhao S. Relationship between the structure - modified N- and C- termini - and the biological activity of TNFα molecule. Acta Genetica Sinica 1995; 22:329-35

Review & Book Chapters

1. Li X and Mobley HLT. Bacterial pili and fimbriae. In: Encyclopedia of Life Sciences 2001; John Wiley & Sons, Ltd, Chichester,

2. Jansen AM, Poore CA, Li X, and Mobley HLT. Urinary tract infections caused by bacterial species other than E. coli. In Sussman M (ed): Molecular Medical Microbiology 2001; Academic Press, London, pp 1541-8

3. Coker C, Poore CA, Li X, and Mobley HLT. Pathogenesis of Proteus mirabilis urinary tract infection. Microbes and Infection 2000; 2:1497-505.